Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Points - Neurogene Inc. is a clinical-stage company focused on developing genetic medicines for rare neurological diseases [1] - The company's Compensation Committee approved the grant of non-qualified stock options for a total of 9,390 shares to four new employees [1] - The grant date for these stock options is set for October 1, 2025 [1]